Compare COLL & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLL | IRMD |
|---|---|---|
| Founded | 2002 | 1992 |
| Country | United States | United States |
| Employees | N/A | 160 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2015 | 2014 |
| Metric | COLL | IRMD |
|---|---|---|
| Price | $45.38 | $99.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $51.17 | ★ $72.00 |
| AVG Volume (30 Days) | ★ 512.5K | 77.5K |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.68% |
| EPS Growth | N/A | ★ 13.00 |
| EPS | 1.63 | ★ 1.65 |
| Revenue | ★ $757,067,000.00 | $80,511,268.00 |
| Revenue This Year | $26.17 | $15.17 |
| Revenue Next Year | $3.65 | $10.15 |
| P/E Ratio | ★ $28.19 | $60.84 |
| Revenue Growth | ★ 26.34 | 12.91 |
| 52 Week Low | $23.23 | $47.48 |
| 52 Week High | $50.79 | $104.93 |
| Indicator | COLL | IRMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 53.70 |
| Support Level | $44.43 | $99.57 |
| Resistance Level | $48.29 | $104.93 |
| Average True Range (ATR) | 2.15 | 2.69 |
| MACD | -0.25 | -0.35 |
| Stochastic Oscillator | 31.27 | 39.32 |
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.